Hutchmed (HCM) news
Recent news
Hutchmed: Global trial of KRAS-EGFR-antibody conjugate therapy
AInvest Wire · Sep 28, 2026Specialty Program Group buys HCM unlocked
Specialty Program Group LLC (SPG), a leading operator of specialty insurance brokerage, underwriting, and consulting facilities, has acquired forensic payroll consulting services . This acquisition aligns with SPG’s ongoing strategy to expand its portfolio through targeted mergers and acquisitions,…
AInvest Wire · Sep 24, 2026Hutchmed China Ltd - Hutchmed licenses KRAS-EGFR-antibody to GSK
HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) has entered into an exclusive development and license agreement with a subsidiary of GSK plc for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate ("ATTC"). The agreement grants the GSK subsidiary worldwide rights,…
AInvest Wire · Sep 3, 2026Hutchmed: Licensing pact with GSK for KRAS-EGFR-antibody conjugate
AInvest Wire · Sep 3, 2026Hutchmed trial shows pfs benefit in met+ EGFR-mutated lung ca
AInvest Wire · Aug 31, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.